Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

Leuk Res. 2011 Apr;35(4):522-5. doi: 10.1016/j.leukres.2010.09.010. Epub 2010 Oct 16.

Abstract

Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / administration & dosage
  • Arsenicals / adverse effects
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Diarrhea / chemically induced
  • Dose-Response Relationship, Drug
  • Fatigue / chemically induced
  • Female
  • Humans
  • Karyotyping
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / mortality
  • Nausea / chemically induced
  • Oxides / administration & dosage
  • Oxides / adverse effects
  • Risk Factors
  • Survival Analysis
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Substances

  • Arsenicals
  • Oxides
  • Cytarabine
  • Arsenic Trioxide